MAPKを標的とする非胃腸筋腫瘍軟組織肉腫の治療:現在の状況と将来の方向性

Ouissam Al Jarroudi^1,2, Khalid El Bairi^3,4, Sami Aziz Brahmi^1,2

¹Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco.

Frontiers in oncology

|September 5, 2025

まとめ

このレビューは,MAPK経路を探索します.

科学分野:

腫瘍学
分子生物学
遺伝学

背景:

非胃腸筋腫瘍 (非GIST) 軟組織肉腫 (STS) は,治療の選択肢が限られている攻撃的な癌です.
STSの分子要因を理解することは標的治療の開発に不可欠です
ミトゲン活性化タンパク質キナーゼ (MAPK) 経路は,肉腫の発症に関与しています.

研究の目的:

非GIST STSにおけるMAPK経路の役割を検討する.
STS治療におけるMAPK阻害剤の有効性を検証する.
MAPK経路を標的とした新興の治療戦略を強調する.

主な方法:

GIST以外のSTSにおけるMAPKシグナル伝達に関する研究の文献レビュー.
MAPK阻害剤を含む現在の治療パラダイムの分析.
MAPKを標的とする新薬に関する最近の臨床前および臨床データの評価

主要な成果:

MAPK経路は,非GIST STSの病原化に大きく貢献しています.
MAPK阻害剤はSTSの標的治療として有望である.
組み合わせた治療法と新しい分子剤が研究されています.

結論:

MAPK経路をターゲットにすると,GIST以外のSTSにとって有望な治療法となる.
バイオマーカーを特定し,治療法を最適化するために,さらなる翻訳的および臨床的研究が必要である.
ナノマテリアルベースの薬物投与は,STSの治療結果を向上させる可能性があります.

キーワード:

MAPK経路について臨床試験精密医療軟組織肉腫標的型療法

さらに関連する動画

07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:15

Drugs that Stabilize Microtubules

2.1K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

2.1K

02:15

M-Cdk Drives Transition Into Mitosis

5.7K

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

5.7K

01:10

Drugs that Destabilize Microtubules

2.0K

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...